Trial Profile
A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Feb 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2023 Results(n=18) assessing molecular characterization of pts with tumors amenable to DNA and RNA sequencing presented at the 2023 Gastrointestinal Cancers Symposium
- 13 Oct 2021 Primary endpoint (Tumor response rate, evaluated according to RECIST 1.1) has not been met, according to Results published in the Clinical Cancer Research .
- 13 Oct 2021 Status changed from active, no longer recruiting to completed, according to Results published in the Clinical Cancer Research .